The Tax-Relief-and-Medicaid-Cuts Bill Nears the Finish Line, With Four Big Implications for the Pharma Industry
Shares:
I’m paying the price for yesterday’s decision to go all-in on the Minnesota 340B report. There’s a lot to get through. Pitter patter. Tomorrow’s Curve will be a game-time decision,
This morning is really kind of out of control, news-wise. There are a number of items here that are worthy of more focus, and I reserve the right to look
Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv